Take Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹187 Cr
- P/E
- 21.37
- ROE
- 16.54%
- PEG
- 0.80
- Price to sales
- 1.64
- Debt to equity
- 0.00
- 52W high / low
- ₹50.1 / ₹10.1
- Sales growth (5Y)
- -41.25%
- EBITDA margin
- 0.29%
- Net profit margin
- 7.86%
- Sales (last year)
- ₹114 Cr
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Take latest results (Sep 2026)
Revenue
₹29 Cr
Net profit
₹2 Cr
-65% YoY
Operating margin
6.02%
EPS
₹0.15
Take shareholding (Sep 2026)
Promoters
0.00%
unchanged QoQ
FIIs
0.21%
+0.01 pp QoQ
DIIs
0.00%
unchanged QoQ
Public
99.79%
−0.01 pp QoQ
Peers
Healthcare Services companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹870 Cr | — | |
| 2 | 40%+ | Flat | ₹576 Cr | 21.9 | |
| 3 | Indegene | 20–40% | Up 2%+ | ₹16,058 Cr | 37.7 |
| 4 | 20–40% | Up 2%+ | ₹1,716 Cr | 17.0 | |
| 5 | 20–40% | Up 2%+ | ₹622 Cr | 20.9 | |
| 6 | 20–40% | Flat | ₹1.23L Cr | 54.1 |
Sign up free to see every company in the sector ranking and track Take.
Pro shows every company guiding 40%+ revenue growth →Full Healthcare Services rankingFinancials of Take
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Shareholder Pattern
Take
Shareholding breakup across reporting periods.
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters + | 53.41% | 53.41% | 53.41% | 53.41% | 53.41% | 53.41% | 53.34% | 5.19% | 0.00% | 0.00% | 0.00% | 0.00% |
| FIIs + | 0.00% | 0.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.56% | 0.28% | 0.20% | 0.21% |
| DIIs + | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.01% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public + | 46.59% | 46.56% | 46.58% | 46.58% | 46.59% | 46.58% | 46.65% | 94.81% | 99.44% | 99.73% | 99.80% | 99.79% |
| No. of Shareholders | 79,336 | 81,938 | 80,288 | 78,033 | 77,163 | 75,988 | 75,141 | 74,410 | 70,324 | 64,699 | 63,213 | 63,302 |
Financials of Take
Quarterly Results
Quarter-by-quarter operating performance
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 54.19 | 30.37 | 29.42 |
| YoY Sales growth | -99.88% | -100.00% | -100.00% | -100.00% | -100.00% | ||||||||
| Expenses + | 1.50 | 1.98 | 15.76 | 2.22 | 0.90 | 2.89 | 1.15 | 0.44 | 0.30 | 0.35 | 55.01 | 30.64 | 27.65 |
| Operating Profit | -1.45 | -1.98 | -15.76 | -2.22 | -0.90 | -2.89 | -1.15 | -0.44 | -0.30 | -0.35 | -0.82 | -0.27 | 1.77 |
| OPM % | -2,900.00% | -1.51% | -0.89% | 6.02% | |||||||||
| Other Income + | 0.41 | 4.07 | -93.70 | -0.97 | -0.23 | 51.31 | -3.48 | -0.29 | 6.92 | 1.46 | 5.18 | 1.33 | 0.44 |
| Interest | 0.56 | 0.54 | 0.54 | 0.49 | 0.50 | 0.73 | 0.24 | 0.18 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.30 | 0.11 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -1.90 | 1.44 | -110.01 | -3.69 | -1.64 | 47.68 | -4.88 | -0.91 | 6.45 | 1.11 | 4.36 | 1.06 | 2.21 |
| Tax % | -18.42% | 248.61% | 0.55% | 1.63% | -3.66% | 0.00% | 0.00% | 0.00% | 2.48% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit + | -1.55 | -2.14 | -110.61 | -3.75 | -1.58 | 47.68 | -4.88 | -0.91 | 6.29 | 1.11 | 4.36 | 1.06 | 2.21 |
| EPS in Rs | -0.10 | -0.14 | -7.48 | -0.25 | -0.11 | 3.22 | -0.33 | -0.06 | 0.43 | 0.08 | 0.29 | 0.07 | 0.15 |
Financials of Take
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 730 | 1,030 | 1,345 | 1,587 | 2,039 | 2,213 | 774 | 655 | 189 | 4 | 0 | 54 | 114 |
| Sales growth | -10% | +41% | +31% | +18% | +28% | +9% | -65% | -15% | -71% | -98% | -100% | ||
| Expenses + | 581 | 817 | 1,082 | 1,281 | 1,655 | 2,044 | 847 | 648 | 208 | 24 | 7 | 56 | 114 |
| Operating Profit | 149 | 213 | 262 | 307 | 384 | 169 | -73 | 7 | -19 | -20 | -7 | -2 | 0 |
| OPM % | 20% | 21% | 20% | 19% | 19% | 8% | -9% | 1.1% | -10% | -569% | -3.5% | 0.3% | |
| Other Income + | 8 | 21 | 13 | 6 | 11 | 26 | -211 | -677 | -56 | -92 | 47 | 13 | 8 |
| Interest | 13 | 15 | 23 | 21 | 25 | 41 | 37 | 29 | 7 | 2 | 2 | 0 | 0 |
| Depreciation | 60 | 74 | 87 | 104 | 154 | 167 | 115 | 80 | 17 | 1 | 0 | 0 | 0 |
| Profit before tax | 85 | 145 | 165 | 188 | 216 | -13 | -437 | -779 | -99 | -116 | 37 | 11 | 9 |
| Tax % | 6% | 14% | 11% | 15% | 17% | -15% | 3% | 0% | 2% | 3% | 0% | 1% | |
| Net Profit + | 80 | 125 | 146 | 160 | 178 | -11 | -450 | -782 | -100 | -120 | 37 | 11 | 9 |
| EPS in Rs | 5.71 | 9.78 | 10.74 | 10.85 | 11.99 | -0.84 | -30.56 | -52.88 | -6.78 | -8.09 | 2.53 | 0.73 | 0.59 |
| Dividend Payout % | 17% | 10% | 9% | 15% | 8% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Financials of Take
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 12 | 12 | 13 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 512 | 619 | 898 | 1,314 | 1,504 | 1,561 | 1,110 | 166 | 94 | -24 | 6 | 16 | 19 |
| Borrowings + | 209 | 336 | 237 | 323 | 474 | 553 | 514 | 59 | 46 | 37 | 0 | 0 | 0 |
| Other Liabilities + | 189 | 246 | 221 | 189 | 339 | 336 | 187 | 984 | 69 | 60 | 16 | 5 | 6 |
| Total Liabilities | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 | 88 | 36 | 36 | 40 |
| Fixed Assets + | 359 | 543 | 554 | 589 | 1,091 | 1,234 | 934 | 101 | 73 | 30 | 0 | 0 | 0 |
| CWIP | 17 | 3 | 21 | 42 | 41 | 1 | 0 | 3 | 11 | 0 | 0 | 0 | 0 |
| Investments | 6 | 21 | 10 | 59 | 10 | 18 | 7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets + | 541 | 647 | 785 | 1,150 | 1,188 | 1,213 | 885 | 1,119 | 140 | 58 | 36 | 36 | 40 |
| Total Assets | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 | 88 | 36 | 36 | 40 |
Financials of Take
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 74 | 151 | 56 | 121 | 104 | 211 | 135 | 30 | 20 | 9 | -16 | -4 |
| Cash from Investing Activity + | -14 | -292 | -130 | -179 | -474 | -233 | -57 | 15 | -3 | -7 | 22 | 2 |
| Cash from Financing Activity + | -11 | 111 | 56 | 302 | 100 | 21 | -84 | -55 | -36 | -12 | -3 | -1 |
| Net Cash Flow | 49 | -30 | -18 | 243 | -270 | -2 | -6 | -10 | -18 | -10 | 3 | -3 |
| Free Cash Flow | 46 | 35 | -30 | 39 | -23 | 54 | 133 | -2 | -12 | 2 | -16 | -4 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 52% | 76% | 26% | 44% | 30% | 156% | -212% | 704% | -114% | -43% | 217% | 208% |
Financials of Take
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 | 715 | 1 | |
| Inventory Days | 0 | |||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 | 715 | 1 | |
| Working Capital Days | 42 | 19 | 90 | 85 | 67 | 80 | 140 | 28 | -42 | -5,559 | 123 | |
| ROCE % | 13% | 16% | 17% | 15% | 13% | 1% | -9% | -6% | -14% | -22% | 11% | 19% |
Take: frequently asked questions
What is Take share price today?
Take last traded at ₹12.62, with a market capitalisation of ₹187 Cr and a P/E ratio of 21.4.
What were Take's latest quarterly results?
For the quarter ended Sep 2026, Take reported revenue of ₹29 Cr and net profit of ₹2 Cr, with an operating margin of 6.02%.
Is Take's profit growing?
Net profit was ₹2 Cr in Sep 2026 against ₹6 Cr in Sep 2025, a change of -65%.
What is Take's EPS?
Take's earnings per share for the quarter ended Sep 2026 was ₹0.15.
What is the promoter holding in Take?
Promoters held 0.00% of Take in Sep 2026 (unchanged versus Jun 2026).
How much do FIIs and DIIs hold in Take?
In Sep 2026, foreign institutional investors held 0.21% and domestic institutions (including mutual funds) held 0.00% of Take.
What is Take's ROE and ROCE?
Take's return on equity is 16.5% and its return on capital employed is 18.5%.
Does Take pay a dividend?
Take's dividend yield is 0% at the current price; see the Take dividends page for past payouts.
Which sector does Take belong to?
Take is in the Healthcare Services sector. Its peer comparison and sector ranking are on this page.
What did Take's management say on the latest earnings call?
Arthneeti's analysis of the Q2 FY27 earnings call covers revenue, margins, capex and fundraising guidance from Take's management.
How does Arthneeti AI analyse Take?
Arthneeti reads Take's earnings call transcripts and filings and scores revenue growth, margins, capex and fundraising, then ranks the company against its sector.
Continue your research
What Take's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
